Advanced search
Publication Cover
Cancer Biology & Therapy Volume 21, 2020 - Issue 3
Submit an article Journal homepage
3,704
Views
13
CrossRef citations to date
0
Altmetric
Bedside-to-Bench Report

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Daniele FrisoneDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3737-3292View further author information
ORCID Icon,
Melinda CharrierDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Sophie ClementDepartment of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Yann ChristinatDepartment of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Laure ThouveninDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Krisztian HomicskoMultidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-0912-6198View further author information
ORCID Icon,
Olivier MichielinMultidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, SwitzerlandView further author information
,
Alexandre BodmerDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Pierre O. ChappuisDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland;Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
,
Thomas A. McKeeDepartment of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, SwitzerlandView further author information
&
Petros TsantoulisDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland;Department of Medical Specialties Faculty of Medicine, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-3613-6682View further author information
ORCID Icon show all
Pages 197-202 | Received 19 May 2019, Accepted 22 Oct 2019, Published online: 10 Nov 2019

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Weiming Fan, Chuan Wang, Xuefeng Zhong, Yating Zheng, Tingting Chen, Mengli Huang & Shuying Su. (2023) A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib. OncoTargets and Therapy 16, pages 23-29.
Read now
Ioannis A Voutsadakis. (2020) Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets. Cancer Management and Research 12, pages 10423-10437.
Read now

Articles from other publishers (11)

Benjamin B. Albright, Stephanie Shuey, Angeles Alvarez Secord, Laura J. Havrilesky, Andrew Berchuck & Rebecca A. Previs. (2023) Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series. Gynecologic Oncology Reports 50, pages 101297.
Crossref
Amanda C. Lorentzian, Jenna Rever, Enes K. Ergin, Meiyun Guo, Neha M. Akella, Nina Rolf, C. James Lim, Gregor S. D. Reid, Christopher A. Maxwell & Philipp F. Lange. (2023) Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. Nature Communications 14:1.
Crossref
Kwong-Kwok Wong, Nicholas W. Bateman, Chun Wai Ng, Yvonne T. M. Tsang, Charlotte S. Sun, Joseph Celestino, Tri V. Nguyen, Anais Malpica, R. Tyler Hillman, Jianhua Zhang, P. Andrew Futreal, Christine Rojas, Kelly A. Conrads, Brian L. Hood, Clifton L. Dalgard, Matthew D. Wilkerson, Neil T. Phippen, Thomas P. Conrads, George L. Maxwell, Anil K. Sood & David M. Gershenson. (2022) Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Journal of Translational Medicine 20:1.
Crossref
Rebecca A. Sager, Sarah J. Backe, Elham Ahanin, Garrett Smith, Imad Nsouli, Mark R. Woodford, Gennady Bratslavsky, Dimitra Bourboulia & Mehdi Mollapour. (2022) Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology 19:5, pages 305-320.
Crossref
Yi Zhang, Zhuo Ma, Ximu Sun, Xin Feng & Zhuoling An. (2022) Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. The Breast 62, pages 162-169.
Crossref
Le Ou-Yang, Dehan Cai, Xiao-Fei Zhang & Hong Yan. (2021) WDNE: an integrative graphical model for inferring differential networks from multi-platform gene expression data with missing values. Briefings in Bioinformatics 22:6.
Crossref
Toshiaki Akahane, Naoki Kanomata, Oi Harada, Tetsumasa Yamashita, Junichi Kurebayashi, Akihide Tanimoto & Takuya Moriya. (2020) Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions. BMC Cancer 20:1.
Crossref
Dai Wee Lee & Gwo Fuang Ho. (2020) Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports 34, pages 100626.
Crossref
Rossana Roncato, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore-Bianchi, Salvatore Siena, Elena De Mattia, Francesco Scaglione & Giuseppe Toffoli. (2020) CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences 21:17, pages 6350.
Crossref
. (2020) Letrozole/palbociclib. Reactions Weekly 1797:1, pages 155-155.
Crossref
Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, Nathan R. Foster, Erik J. Asmus, Andrea Wahner Hendrickson, Aminah Jatoi, Matthew S. Block, Carrie L. Langstraat, Gretchen E. Glaser, Tri A. Dinh, Matthew W. Robertson, John K. Camoriano, Kristina A. Butler, John A. Copland & S. John Weroha. (2020) Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open 5:5, pages e000926.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.